- Curran Simpson has been
appointed Chief Operating Officer
- Shiva Fritsch assumes the role of Chief Communications
Officer
ROCKVILLE, Md., Jan. 9, 2023
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced
the promotion of Curran Simpson from
Chief Technology and Operations Officer to Chief Operating Officer.
In addition, Shiva Fritsch has been elevated to Chief
Communications Officer and will continue in her role as Chief
People Officer.
"These appointments come on the heels of a transformational year
for REGENXBIO, highlighted by the opening of the company's gene
therapy Manufacturing Innovation Center and the advancement of
several clinical programs as part of our '5 x '25' strategy to
progress five AAV Therapeutics from the pipeline and licensed
programs into pivotal-stage or commercial products by 2025," said
Kenneth T. Mills, President and
Chief Executive Officer of REGENXBIO. "Curran and Shiva are strong,
collaborative leaders with proven track-records. They have played
critical roles in the evolution of REGENXBIO into a near-commercial
stage company. These promotions reflect on their contributions to
date and their ability to lead the organization as we enter the
next phase of growth. We are incredibly fortunate to have
them."
Mr. Simpson joined REGENXBIO in 2015 with extensive leadership
experience across biopharmaceutical operations, manufacturing,
supply chain, research and engineering roles. As Chief Operating
Officer, he will have oversight of manufacturing, process
development, quality, regulatory, preclinical development and
bioanalytical sciences, as well as corporate strategy. Prior to
joining REGENXBIO, he served as the Regional Supply Chain Head for
North America at GlaxoSmithKline
plc ("GSK"). Prior to that, he was the Senior Vice President,
Operations at Human Genome Sciences (HGS), as well as the Vice
President, Manufacturing Operations at HGS. Prior to HGS, Mr.
Simpson held various positions with Biogen, Inc., Covance
Biotechnology Services Inc., Novo-Nordisk Biochem Inc., Genentech,
Inc. and Genencor, Inc. Mr. Simpson received an M.S. in Surface and
Colloid Science (Physical Chemistry) from Clarkson University and a B.S. in
Chemistry/Chemical Engineering from Clarkson
College of Technology.
Ms. Fritsch joined REGENXBIO in 2017 and has over two decades of
experience in research, development and human resources in the
biopharmaceutical industry. As Chief Communications and People
Officer, she will oversee all elements of REGENXBIO's internal and
external communications, as well as its robust human resource
offerings. Prior to joining REGENXBIO in 2017, Ms. Fritsch was the
Head of Talent Management at Novavax, Inc. and held senior human
resources roles at the Howard Hughes Medical Institute and Human
Genome Sciences, Inc. Ms. Fritsch holds an M.B.A from the Robert H.
Smith School of Business at the University of
Maryland, College Park, as well as a B.A in Biology and
Neurobiology from Bryn Mawr
College.
About REGENXBIO
Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates,
including late-stage and commercial programs, in multiple
therapeutic areas. REGENXBIO is committed to a "5 x '25" strategy
to progress five AAV Therapeutics from our internal pipeline and
licensed programs into pivotal-stage or commercial products by
2025.
Forward-Looking
Statements
This press release includes "forward-looking statements," within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements express a belief, expectation or
intention and are generally accompanied by words that convey
projected future events or outcomes such as "believe," "may,"
"will," "estimate," "continue," "anticipate," "assume," "design,"
"intend," "expect," "could," "plan," "potential," "predict,"
"seek," "should," "would" or by variations of such words or by
similar expressions. The forward-looking statements include
statements relating to, among other things, REGENXBIO's
expectations and evaluations of its management team, future
operations and clinical trials. REGENXBIO has based these
forward-looking statements on its current expectations and
assumptions and analyses made by REGENXBIO in light of its
experience and its perception of historical trends, current
conditions and expected future developments, as well as other
factors REGENXBIO believes are appropriate under the circumstances.
However, whether actual results and developments will conform with
REGENXBIO's expectations and predictions is subject to a number of
risks and uncertainties, many of which are beyond the control of
REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion
and Analysis of Financial Condition and Results of Operations"
sections of REGENXBIO's Annual Report on Form 10-K for the year
ended December 31, 2021, and
comparable "risk factors" sections of REGENXBIO's Quarterly Reports
on Form 10-Q and other filings, which have been filed with the U.S.
Securities and Exchange Commission (SEC) and are available on the
SEC's website at www.sec.gov. All of the forward-looking statements
made in this press release are expressly qualified by the
cautionary statements contained or referred to herein. The actual
results or developments anticipated may not be realized or, even if
substantially realized, they may not have the expected consequences
to or effects on REGENXBIO or its businesses or operations. Such
statements are not guarantees of future performance and actual
results or developments may differ materially from those projected
in the forward-looking statements. Readers are cautioned not to
rely too heavily on the forward-looking statements contained in
this press release. These forward-looking statements speak only as
of the date of this press release. Except as required by law,
REGENXBIO does not undertake any obligation, and specifically
declines any obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-senior-leadership-promotions-301716977.html
SOURCE REGENXBIO Inc.